Encorafenib is a medication used in this trial to target a specific mutation in cancer cells known as BRAF V600E. It works by blocking the activity of a protein that promotes cancer cell growth, helping to slow down or stop the progression of the cancer.

Cetuximab is a therapy that targets a protein on the surface of cancer cells called EGFR. By binding to this protein, cetuximab can help prevent the cancer cells from growing and dividing.

mFOLFOX6 is a combination chemotherapy regimen that includes several drugs working together to kill cancer cells. It is often used to treat colorectal cancer and includes medications that interfere with the DNA of cancer cells, preventing them from multiplying.

FOLFIRI is another chemotherapy regimen used in this trial. It combines different drugs to attack cancer cells in various ways, aiming to reduce the size of tumors and slow the spread of cancer.

Bevacizumab is a medication that works by inhibiting the growth of blood vessels that supply nutrients to tumors. By blocking this blood supply, bevacizumab can help starve the cancer cells and slow their growth.

Colorectal Cancer (BRAF V600E-mutant mCRC) – This is a type of cancer that begins in the colon or rectum and is characterized by a specific genetic mutation known as BRAF V600E. This mutation can lead to uncontrolled cell growth and division, contributing to the development and progression of cancer. The disease often starts as a small growth, called a polyp, on the inner lining of the colon or rectum, which can become cancerous over time. As the cancer progresses, it can invade deeper layers of the colon or rectum and spread to nearby lymph nodes or other parts of the body. The presence of the BRAF V600E mutation is associated with a more aggressive form of colorectal cancer, which may influence the disease’s behavior and response to certain treatments.